FORSCEY, PLLC for BARR LABORATORIES
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 14, 2009 | $60,000 | Replaced |
| 4th Quarter - Termination Amendment (this page) | Feb 19, 2009 | $60,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Opposition to changes in legal doctrines of inequitable conduct that would make it harder for generic drug firms to pursue invalidity claims; S. 1145 Patent Reform Act of 2007.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL A FORSCEY | Managing Partner |
Health Issues HCR
Advance proposal to create an FDA process for the approval of generic biological products; S. 316 - Preserve Access to Affordable Generics Act; H.R. 1902 - Protecting Consumer Access to Generic Drugs Act; H.R. 1038 - Access to Life Saving Medicine Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL A FORSCEY | Managing Partner |
| JOHN STINSON | Partner |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.